Olympiad Research LP Invests $287,000 in Astrana Health, Inc. (NASDAQ:ASTH)

Olympiad Research LP purchased a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 9,106 shares of the company’s stock, valued at approximately $287,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ASTH. State Street Corp acquired a new position in shares of Astrana Health during the third quarter worth about $91,966,000. Geode Capital Management LLC acquired a new position in shares of Astrana Health during the third quarter worth about $58,995,000. FMR LLC acquired a new position in Astrana Health during the third quarter worth about $48,413,000. SteelPeak Wealth LLC acquired a new position in Astrana Health during the third quarter worth about $39,398,000. Finally, Loomis Sayles & Co. L P acquired a new position in Astrana Health during the third quarter worth about $30,251,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Macquarie upgraded shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. Truist Financial lowered their target price on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Robert W. Baird upped their target price on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Stifel Nicolaus lowered their target price on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Astrana Health has an average rating of “Moderate Buy” and an average target price of $63.00.

Astrana Health Stock Down 4.6 %

ASTH stock opened at $35.68 on Friday. The company’s 50 day simple moving average is $35.06 and its 200-day simple moving average is $44.97. The firm has a market capitalization of $2.01 billion, a PE ratio of 27.45, a P/E/G ratio of 1.44 and a beta of 1.20. Astrana Health, Inc. has a 12 month low of $29.08 and a 12 month high of $63.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.